ZLife Technologies is a biotechnology company developing innovative solutions for
targeting ischemia-reperfusion injury, to be used in organ and tissue
transplantation, cardiothoracic and vascular surgery, and clinical
management of heart attack, stroke and trauma.
ZLife Technologies is developing a novel preservation solution, ZL Solution, as a clinical treatment for ischemia-reperfusion injury in organ transplantation, particularly intestinal transplantation. Preclinical proof of concept has been demonstrated, with excellent results for 24-hour preservation of mouse and human intestinal tissues. A provisional patent has been obtained, and ZLife Technologies is 12-18 months from filing an IND to begin an initial clinical trial. The solution has the potential to be effective in preserving other tissues, e.g. kidney, for transplantation. The goal of ZLife Technologies is to further develop and commercialize this novel preservation solution as a clinical treatment for I/R injury in intestinal transplantation and other forms of organ transplantation. The potential market value is $200 million annually.
The ZLife Technologies Team
Ming Zhang, MD, PhD (Founder)
Research Associate Professor of Anesthesiology and Cell Biology
State University of New York Downstate Medical Center
Dr. Zhang received his medical degree from Sichuan University-West China Center of Medical Sciences, and his PhD from the Rutgers University New Jersey Medical School. He did his postdoctoral fellowship in the laboratory of Dr. Michael Carroll at Harvard Medical School, where he pioneered the discovery of a monoclonal autoreactive IgM antibody against a specific self-antigen in ischemia-reperfusion injury. He was recruited to State University of New York Downstate Medical Center to expand his research into multiple basic science, translational and clinical areas, including cardiovascular diseases, pregnancy hypertension, and transplantation rejection.